최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기Menopause : journal of the North American Menopause Society, v.15 no.2, 2008년, pp.296 - 303
Kong, Mi-Hee (From the Departments of 1Family Practice, 2Radiology, and 3Preventive Medicine and Public Health, College of Medicine, Ajou University, Suwon, Korea) , Lee, Eun-Ju (4Department of Pathology, College of Medicine, Hallym University, Seoul, Korea) , Lee, Soon-Yong (and 5Department of Internal Medicine, College of Medicine, Ewha Woman's University, Seoul, Korea.) , Cho, Seong-Jin , Hong, Young-Sun , Park, Sat-Byul
OBJECTIVE:: In Korea, human placental extract (HPE) has recently been used to treat various diseases (chronic liver diseases, menopause syndrome, chronic fatigue, skin pigment diseases, etc.), but evidence-based studies are not yet sufficient. The aim of this study was to examine the effects of HPE on menopausal symptoms, fatigue, and risk factors for cardiovascular disease in middle-aged Korean women in a randomized controlled trial. DESIGN:: Korean women, aged 40 to 64 years, with menopausal symptoms and fatigue were recruited as participants. The women were randomly assigned to a placebo group or an HPE group. The HPE group received subcutaneous injections of HPE in the abdomen for 8 weeks, whereas the placebo group received normal saline. Then, the Menopause Rating Scale, and Fatigue Severity Scale, and Visual Analog Scale were administered, and risk factors for cardiovascular disease were assessed. RESULTS:: The Menopause Rating Scale total baseline score was not different between the two groups; however, the score of the HPE group decreased significantly at 8 weeks compared with that of the placebo group (P = 0.033). Fatigue Severity Scale and Visual Analog Scale scores of the placebo group did not change, whereas the scores of the HPE group decreased significantly during the study period (Fatigue Severity Scale, P = 0.002; Visual Analog Scale, P = 0.001). The baseline 17&bgr;-estradiol level was not significantly different between the two groups, but the 17&bgr;-estradiol level of the HPE group was significantly increased at 8 weeks compared with that of the placebo group (P = 0.031). No changes in risk factors for cardiovascular disease were observed in either group. CONCLUSIONS:: Menopausal symptoms and fatigue in middle-aged Korean women improved after 8 weeks of HPE treatment, whereas risk factors for cardiovascular disease did not change during the study period.
Sakamoto Jpn J Pharmacol 1986 10.1254/jjp.41.424 41 424
Nakayama Nippon Yakurigaku Zasshi 1989 10.1254/fpj.94.289 94 289
Liu Biol Pharm Bull 1998 10.1248/bpb.21.44 21 44
Nakayama Nippon Yakurigaku Zasshi 1989 10.1254/fpj.94.137 94 137
Kim Korean J Dermatol 2003 41 1612
Itho Fragrance J 1990 6 67
Pal Int J Dermatol 2002 10.1046/j.1365-4362.2002.01524.x 41 760
Mallick Pigment Cell Res 2005 10.1111/j.1600-0749.2004.00193.x 18 25
Suite J Am Acad Dermatol 1991 10.1016/S0190-9622(08)80121-1 24 1018
Sarkar Mol Cell Biochem 2006 10.1007/s11010-005-9069-3 285 133
Matthews Stroke 2001 10.1161/01.STR.32.5.1104 32 1104
Matthews Arch Intern Med 1994 10.1001/archinte.1994.00420200105011 154 2349
Lyndaker J Obstet Gynecol Neonatal Nurs 2004 10.1177/0884217504264872 33 340
Matthews Diabetologia 1985 10.1007/BF00280883 28 412
Katz J Clin Endocrinol Metab 2000 10.1210/jcem.85.7.6661 85 2402
Heinemann Health Qual Life Outcomes 2003 10.1186/1477-7525-1-28 1 28
Heinemann Health Qual Life Outcomes 2004 10.1186/1477-7525-2-45 2 45
Hauser Zentralbl Gynakol 1994 116 16
Schneider Climacteric 2000 10.3109/13697130009167600 3 59
Krupp Arch Neurol 1989 10.1001/archneur.1989.00520460115022 46 1121
Chung Korean J Psychosom Med 2001 9 164
Bates Arch Intern Med 1993 10.1001/archinte.1993.00410240067007 153 2759
Kim J Korean Med Sci 2005 10.3346/jkms.2005.20.4.529 20 529
Chalder J Psychosom Res 1993 10.1016/0022-3999(93)90081-P 37 147
Devanur J Clin Virol 2006 10.1016/j.jcv.2006.08.013 37 139
Sur Acta Pharmacol Sin 2003 24 187
Banerjee Riv Eur Sci Med Farmacol 1992 14 361
Biswas Acta Pharmacol Sin 2001 22 1113
Shukla J Wound Care 2004 10.12968/jowc.2004.13.5.26668 13 177
Chakraborty J Chromatogr B Analyt Technol Biomed Life Sci 2005 10.1016/j.jchromb.2004.09.059 818 67
Kaushal Int J Tissue React 2001 23 105
Atkins Clin Cancer Res 2004 10.1158/1078-0432.CCR-040029 10 6342S
Shibasaki J Clin Endocrinol Metab 1982 10.1210/jcem-55-2-384 55 384
Carotti Physiol Chem Phys 1981 13 129
Wilbur Health Care Women Int 2006 10.1080/07399330600803741 27 600
Hashimoto Circulation 2001 10.1161/hc2601.091705 104 63
Ridker Circulation 2004 10.1161/01.CIR.0000132467.45278.59 109 2818
Hutton Thromb Res 1980 10.1016/0049-3848(80)90081-X 17 465
Wolf Am J Pathol 1991 138 1035
Saito J Biochem (Tokyo) 1995 10.1093/jb/117.2.276 117 671
Corson Int J Fertil Womens Med 1999 44 279
Kurman Obstet Gynecol 2000 96 373
Utian Fertil Steril 2001 10.1016/S0015-0282(01)01791-5 75 1065
Rossouw JAMA 2002 10.1001/jama.288.3.321 288 321
※ AI-Helper는 부적절한 답변을 할 수 있습니다.